Drugs / Autologous Anti-CD19 CAR-expressing T Lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05707273 | Apr 2023 → Jul 2026 overdue | B-cell acute lymphoblastic leukemia | City of Hope Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Anti-CD19 CAR-expressing T Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05707273 ↗ |
| Modality | Cell therapy | “CAR T-cell therapy is a type of treatment” NCT05707273 ↗ |
| Route | Intravenous | “Given IV” NCT05707273 ↗ |
| Target | CD19 | “autologous anti-CD19 CAR-expressing T lymphocytes” NCT05707273 ↗ |